Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma by O'Connor, O A
Clinical experience with the novel histone deacetylase inhibitor
vorinostat (suberoylanilide hydroxamic acid) in patients with
relapsed lymphoma
OA O’Connor*,1
1Laboratory of Experimental Therapeutics, Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering
Cancer Center, New York, NY, USA
Preclinical studies indicate that vorinostat (suberoylanilide hydroxamic acid or SAHA) inhibits histone deacetylase (HDAC) activity,
increases acetylated histones H2a, H2b, H3, and H4, and thereby induces differentiation and apoptosis in a variety of tumour cell
lines, including murine erythroleukaemia, human bladder transitional cell carcinoma, and human breast adenocarcinoma. On the basis
of these favourable preclinical findings, vorinostat has been selected as a candidate for clinical development with the potential to treat
patients with selected malignances, including Hodgkin’s disease and non-Hodgkin’s lymphomas. Phase I clinical trials in patients with
haematological malignances and solid tumours showed that both intravenous (i.v.) and oral formulations of vorinostat are well
tolerated, can inhibit HDAC activity in peripheral blood mononuclear cells and tumour tissue biopsies, and produce objective tumour
regression and symptomatic improvement with little clinical toxicity. The dose-limiting toxicities (DLT) of i.v. vorinostat were primarily
haematologic and were rapidly reversible within 4–5 days of therapy cessation. In contrast, the DLT for oral vorinostat were primarily
non-haematologic (including dehydration, anorexia, diarrhoea, fatigue) and were also rapidly reversible, usually within 3 days. Further
research is warranted to optimise the dosing schedule for vorinostat, particularly with respect to dose, timing of administration, and
duration of therapy, and to fully delineate the mechanism(s) of antitumour effect of vorinostat in various types of malignances. Several
phase II studies are currently ongoing in patients with haematological malignances and solid tumours.
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The potential therapeutic benefit created by facilitated gene
transcription has led to the development of histone deacetylase
(HDAC) inhibitors, which have the capacity to induce cytodiffer-
entiation, and cause cell-cycle arrest and apoptosis of transformed
cells (Marks et al, 2004). One such HDAC inhibitor, vorinostat
(suberoylanilide hydroxamic acid or SAHA), has been shown to
induce differentiation of murine erythroleukaemia (Richon et al,
1996), human bladder transitional cell carcinoma (T24) (Richon
et al, 2000), and human breast adenocarcinoma (MCF-7) (Huang
and Pardee, 2000; Munster et al, 2001). Vorinostat inhibits HDAC
through a direct interaction with the enzymes catalytic site,
resulting in accumulation of acetylated histones H2a, H2b, H3,
and H4. Based on the biological rationale and early preclinical
data summarised above, vorinostat was selected as a candidate for
clinical development. This article will summarise the toxicity,
pharmacokinetic and pharmacodynamic profiles, and efficacy of
intravenous (i.v.) and oral formulations of vorinostat, and review
the findings from initial phase I studies that revealed interesting
differences in toxicity profile between the two formulations.
Additional reviews regarding the biological aspects of HDACs
can be found elsewhere (Marks et al, 1999; Marks et al, 2000;
Marks et al, 2001; Dokmanovic and Marks, 2005; Marks and
Dokmanovic, 2005).
BCL-6 AS A THERAPEUTIC TARGET—RATIONALE
FOR USE OF VORINOSTAT TO TREAT LYMPHOMA
The proto-oncogene BCL-6, located at chromosome 3q27, encodes
a POZ/zinc finger sequence-specific transcriptional repressor and
represents one of three genes commonly implicated in non-
Hodgkin’s lymphoma (NHL)(the other two genes are BCL-2 and
c-myc) (Ye et al, 1993a,b; Lo et al, 1994; Kramer et al, 1998;
Pasqualucci et al, 2003). BCL-6 is constitutively expressed in a
large proportion of B-cell lymphomas where it appears to suppress
genes involved in the control of lymphocyte activation, differ-
entiation, and apoptosis (Pasqualucci et al, 2003). Recent studies
suggest that the transcriptional co-activator p300 acetylates BCL-6
and, in doing so, disrupts the ability of BCL-6 to recruit HDACs,
thereby compromising its ability to repress transcription and
induce cell transformation (Bereshchenko et al, 2002). This has
important therapeutic ramifications in that pharmacological
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www.bjcancer.cominhibition of HDACs might be expected to result in the
accumulation of the inactive acetylated BCL-6 which can then
induce cell-cycle arrest and death of B-cell lymphoma cells
(Figure 1). This hypothesis is supported by the observation that
the HDAC inhibitor trichostatin A (TSA) results in apoptosis in
several cell lines of B-NHL(Pasqualucci et al, 2003). Collectively,
these studies suggest that HDAC inhibitors such as vorinostat may
represent a novel therapeutic approach to treat patients with
certain types of lymphomas.
INTRAVENOUS AND ORAL FORMULATIONS OF
VORINOSTAT
Dose-escalating studies with daily 2-h i.v. infusions of vorinostat
administered 5 days per week for up to 3 consecutive weeks
demonstrated that an i.v. formulation could be administered safely
to patients with haematological and solid tumours (Kelly et al,
2003). Peak vorinostat concentrations occurred approximately
60min after beginning the infusion (range 25–120min). The
terminal half-life of i.v. vorinostat ranged from 21 to 58min, and
the area under the plasma concentration curve was proportional to
the dose administered. At all i.v. doses of vorinostat studied (75,
150, 300, 600, and 900mgm
 2day
 1), plasma concentrations
exceeded 2.5mM (Figure 2), a concentration that inhibits cell
proliferation in vitro and results in accumulation of acetylated
histones. In addition, i.v. vorinostat was also shown to inhibit
HDAC activity in normal cells (peripheral blood mononuclear
cells) as well as in tumour tissue biopsies. As illustrated in three
patients, accumulation of acetylated histones in peripheral blood
mononuclear cells occurred at the end of a 2-h vorinostat infusion
and was still evident 2h after the infusion ended (Figure 3).
To simplify the administration of vorinostat, an oral formula-
tion was developed, which also shows a favourable pharmaco-
kinetic profile while retaining its antitumour activity. The
bioavailability of oral vorinostat is relatively high (43%) and
appears to be uninfluenced by the consumption of food (Kelly
et al, 2005). Oral vorinostat demonstrated linear pharmacokinetics
from 200 to 600mg, although peak concentrations were lower than
that seen with the i.v. formulation (Kelly et al, 2005). The apparent
half-life of oral vorinostat ranged from 91 to 127min, values that
were 2–3-fold higher than those determined after i.v. administra-
tion. Plasma concentrations of vorinostat were detectable at least
10h post-ingestion, whereas vorinostat was undetectable in plasma
4–6h after i.v. dosing. As observed following i.v. administration,
oral vorinostat consistently effected accumulation of acetylated
histones in peripheral blood mononuclear cells at 2h post-dosing,
an effect that persisted for up to 10h after a single dose of 400mg
or higher (Kelly et al, 2005). Histone acetylation was still apparent
in patients receiving oral vorinostat for 6 months or longer.
COMPARISON OF ORAL AND I.V. VORINOSTAT IN
PHASE I STUDIES
The antitumour effects of oral and i.v. formulations of vorinostat
have been assessed in two Phase I clinical trials (Kelly et al, 2003,
2005). In both of these trials, escalation of vorinostat was
carried out in parallel and independently in patients with solid
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Figure 1 BCL-6 is constitutively expressed in a large proportion of B-cell
lymphomas and is involved in the suppression of genes involved in the
control of lymphocyte activation, differentiation, and apoptosis. In the
acetylated state, BCL-6 is inactive and loses its ability to repress
transcription and to induce cell transformation. Pharmacological inhibition
of HDAC with agents such as vorinostat may result in the accumulation
of acetylated BCL-6, expression of the cell-cycle regulator p21
WAF1 and
ultimately growth inhibition, apoptosis, and differentiation of B-cell
lymphoma cells.
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Figure 2 Mean plasma vorinostat concentrations over time following
escalating i.v. vorinostat doses in patients with advanced cancer.
Reproduced with permission from Kelly et al (2003).
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Figure 3 Effect of i.v. vorinostat on histone acetylation in mononuclear
cells (by Western blot analysis using a rabbit purified polyclonal anti-
acetylated histone H3 antibody) obtained from three cancer patients. As a
loading control for histone proteins, parallel gels were run and stained with
Coomassie (CS). Peripheral whole blood was collected from each patient
before (pre) and at the end of a 2-h vorinostat infusion (post), as well as 2h
after completion of infusion (post 2h).
Vorinostat for advanced haematological malignancies
OA O’Connor
S8
British Journal of Cancer (2006) 95(S1), S7–S12 & 2006 Cancer Research UKtumours and haematological malignances. The present review
primarily focuses on data obtained in patients with advanced
haematological malignances who had failed or relapsed following
standard therapy (O’Connor et al, 2006). The patient population
included those with refractory or relapsed leukaemia, multiple
myeloma, indolent or aggressive NHL, mantle cell lymphoma,
and Hodgkin’s disease (HD). Eligible patients were required to
have a Karnofsky performance status of at least 70, adequate
renal and hepatic function, an absolute neutrophil count of
X500cellsmm
 3, and a platelet count of 425000cellsmm
 3, and
no serious comorbidities.
A total of 39 patients with haematological malignancy were
registered, of which 35 were treated with either i.v. vorinostat or
oral vorinostat (Table 1). Compared with the i.v. vorinostat group,
patients receiving oral vorinostat showed a greater variation in the
types of underlying haematological malignancy. The majority of
patients in both groups were heavily pretreated, with some patients
having received up to 15 different chemotherapy or biological
therapies before study enrolment. In addition, between 35 and
50% of patients had received prior stem cell transplantation and
approximately half of all patients had previously received therapy
with rituximab. The duration of therapy was longer in patients
receiving oral vorinostat compared with patients receiving i.v.
vorinostat (average 14.1 vs 10.5 weeks, respectively). However, the
largest difference between the study groups was age, with patients
receiving i.v. vorinostat being considerably younger than patients
receiving oral vorinostat (median age 39 vs 57 years, respectively).
SAFETY AND TOLERABILITY
Overall, both vorinostat formulations were well tolerated (Kelly
et al, 2003, 2005; O’Connor et al, 2006). Major adverse events with
oral vorinostat included fatigue, diarrhoea, anorexia, and dehy-
dration, whereas myelosuppression and thrombocytopenia were
more prominent with i.v. vorinostat (Table 2). Typically, the
haematological toxicities, especially the thrombocytopenia, re-
solved shortly after vorinostat therapy was stopped, suggesting
that toxicity did not affect megakaryocytes directly, but may have
add an affect on the terminal budding stage of platelet formation.
This was confirmed on evaluation of bone marrow biopsy
specimens obtained at the platelet nadir, which demonstrated
ample numbers of megakaryoctyes, most of which had actually lost
their characteristic appearance, and failed to demonstrate evidence
of terminal budding. There were no incidents of neutropenic fever
or neutropenic sepsis.
The number of patients with dose-limiting toxicities (DLTs),
defined as either grade 3 or 4 non-haematologic toxicities or
treatment delay for toxicity for longer than 1 week, for each dose
level in the i.v. or oral vorinostat groups are summarised in
Table 3. Dehydration, diarrhoea, and fatigue were the predominant
DLTs in patients receiving oral vorinostat. The 400mg daily oral
dose was the best tolerated, with only 18% of patients experiencing
DLT. In patients receiving i.v. vorinostat, neutropenia or
thrombocytopenia as well as dehydration and diarrhoea were the
most frequent DLTs.
ANTITUMOUR ACTIVITY
Intravenous vorinostat resulted in antitumour activity in three
patients with HD who had previously failed autologous transplants
(Table 4) (Kelly et al, 2003, 2005; O’Connor et al, 2006). One HD
patient, who was maintained on vorinostat at a dose of 300mgm
 2
for 9 months, showed stabilisation of her disease on a computed
tomography (CT) scan and normalisation of her positron emission
tomography (PET) scan. This patient subsequently converted to
oral vorinostat for ease of therapy. The second HD patient
receiving i.v. vorinostat at a dose of 600mgm
 2 showed a 15%
shrinkage of disease, which was associated with a marked
improvement in her pulmonary and overall performance status
(Figure 4). Her disease subsequently progressed during a period
of therapy cessation owing to secondary systemic infection. The
third HD patient demonstrated an approximately 42% regres-
sion of their disease (durable for 2 months) with symptomatic
improvement.
Table 1 Summary of patient characteristics in i.v. and oral vorinostat
groups
i.v. vorinostat Oral vorinostat
Total number of patients 14 Registered 25 Registered
12 Treated 23 Treated
Male 7 (58%) 16 (69%)
Female 5 (42%) 7 (30%)
Median age 39 (19–77) 57 (20–99)
Diseases
Hodgkin’s disease 5 (42%) 7 (30%)
DLBCL 5 (42%) 7 (30%)
Small lymphocytic 1 (8%) 1 (4%)
Mantle cell NHL — 2 (9%)
CTCL/PTCL 1 (8%) 2 (9%)
Multiple myeloma — 2 (9%)
APL/MDS — 1 (4%)/1 (4%)
Prior chemotherapy or
biological therapies per patient
(median)
7 (4–15) 5 (1–11)
Patients who received prior
stem cell transplant
6 (50%) 8 (35%)
Received rituximab 7 (six non-Hodgkin’s
lymphoma and one
Hodgkin’s disease)
11 (10 non-Hodgkin’s
lymphoma and one
Hodgkin’s disease)
APL¼acute promyelocytic leukaemia; CTCL¼cutaneous T-cell lymphoma;
DLBCL¼diffuse large B-cell lymphoma; i.v.¼intravenous; MDS¼myelodysplastic
syndrome; NHL¼non-Hodgkin’s lymphoma; PTCL¼peripheral T-cell lymphoma;
SAHA¼suberoylanilide hydroxamic acid.
Table 2 Common overall non-haematologic and haematological
toxicities (grades 3 and 4)
i.v. vorinostat
(n¼12)
Oral vorinostat
(n¼23)
Grade 3 Grade 4 Grade 3 Grade 4
Non-haematological toxicities
Anorexia 0 0 3 0
Constipation 1 0 0 0
Diarrhoea 1 0 6 0
Dehydration 0 0 11 0
Dyspnea 2 0 0 0
Fatigue 2 0 5 0
Infection w/o neutropenia 1 0 5 0
Hyperglycemia 0 0 3 0
Hypocalcemia 0 0 1 0
Hypokalemia 0 0 2 0
Hypophosphatemia 1 0 4 0
Neurological, Guillan Barre 0 0 1 0
Pleuritic chest pain 1 0 0 0
Thrombosis 1 0 1 0
Haematological toxicities
Anaemia 5 0 4 3
Leukopenia 1 1 3 1
Neutropenia 0 1 3 1
Thrombocytopenia 1 0 7 1
i.v.¼intravenous, SAHA¼suberoylanilide hydroxamic acid.
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total of four patients, one with HD, two with transformed DBLCL,
and one with cutaneous T-cell lymphoma (CTCL) (Table 4). The
patient with HD showed a 31% tumour response lasting for 9
months, as assessed by CT scan. In the two patients with
transformed DBLCL, both of whom were heavily pretreated before
receiving vorinostat therapy, one experienced a CR lasting for 12
months and one experienced a PR lasting over 5 months. Figure 5
shows the resolution of a gastrohepatic mass over time in one of
the patients with transformed DBLCL who received oral vorinostat.
A substantial reduction in tumour size was apparent after one
cycle of oral vorinostat therapy, and by two cycles, the mass had
completely disappeared. This patient also demonstrated a negative
PET scan performed after 5 months of therapy. The patient with
CTCL exhibited a PR of his skin tumour over 4 months.
CONCLUSIONS
The phase I clinical trial experience in patients with haematolo-
gical malignances showed that both i.v. and oral formulations of
vorinostat are well tolerated. The DLTs of i.v. vorinostat were
primarily haematologic toxicities, which were rapidly reversible
within 4–5 days of therapy cessation. For oral vorinostat, the
DLTs were primarily non-haematologic toxicities (dehydration,
anorexia, diarrhoea, fatigue), which were also rapidly reversible
with a median duration of 3 days. The differences in the types of
DLTs observed between oral and i.v. vorinostat may result from
dissimilarities in the pharmacokinetics of the two formulations.
Intravenous vorinostat administration may give rise to higher Cmax
values and lower AUC values than oral vorinostat, and this may
have important ramifications in terms of the spectrum of toxicities
observed.
Evidence of inhibition of HDAC activity in both PBMNC and
tumour tissue biopsies was apparent for up to 10h following oral
administration of vorinostat. Inhibition of HDAC activity was
associated with objective tumour regression and symptomatic
improvement (with little clinical toxicity) in patients with a variety
of haematological malignances, including HD and select subtypes of
NHL, including T-cell lymphomas. Further studies are needed to
define relevant biologic end points that can be used as a guide to
optimise the dosing schedule for vorinostat, particularly with respect
to dose, timing of administration, and duration of therapy. At the
molecular level, further research is needed to fully delineate the
Table 3 Dose-limiting toxicities (grade 3 or 4 non-haematologic toxicities or treatment delay for toxicity for longer than 1 week) associated with i.v. or
oral vorinostat therapy
i.v. vorinostat Oral vorinostat
Dose level Dose-limiting toxicities Dose level Dose-limiting toxicities
300mgm
 2day
 1 5 day 3 weeks
(n¼7)
None 400mg once daily (n¼11) Dehydration/diarrhoea/fatigue (n¼2)
600mgm
 2day
 1 5 day 3 weeks
(n¼5)
Treatment delay for neutropenia or
thrombocytopenia (n¼2)
400mg twice daily (n¼3) Dehydration/fatigue/anorexia (n¼3)
600mg once daily (n¼3) Dehydration/diarrhoea (n¼2) 600mg once daily (n¼3) Dehydration/fatigue/diarrhoea (n¼2)
200mg twice daily (n¼6) Dehydration/anorexia/fatigue (n¼2)
Table 4 Antitumour activity of i.v. and oral vorinostat
i.v. vorinostat (n¼12) Oral vorinostat (n¼23)
Disease Tumour response by CT scan Disease Tumour response by CT scan
HD PR 9 months tDBLCL CR 412 months
HD SD 2 months tDBLCL PR 45 months
HD SD 3 months HD SD 9 months
CTCL* PR 4 months
CR¼complete remission; CT¼computed tomography; CTCL¼cutaneous T-cell lymphoma; DLBCL¼diffuse large B-cell lymphoma; HD¼Hodgkin’s disease;
i.v.¼intravenous; PR¼partial response; SAHA¼suberoylanilide hydroxamic acid; SD¼stable disease.*Response based on skin examination.
Baseline 2-Month Follow-up
Figure 4 CT scan of thoracic cavity of a patient with refractory HD before and after i.v. vorinostat 600mgm
 2 for 5 days every 3 weeks.
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malignances and to understand why normal cells are apparently
more resistant to apoptosis than transformed cells. Several phase II
studies are currently ongoing in patients with haematological
malignances and solid tumours. The preliminary results of vorino-
stat’s activity in T-cell lymphoma will be discussed by Dr Duvic.
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